91 related articles for article (PubMed ID: 12107842)
1. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.
Donskov F; Bennedsgaard KM; Von Der Maase H; Marcussen N; Fisker R; Jensen JJ; Naredi P; Hokland M
Br J Cancer; 2002 Jul; 87(2):194-201. PubMed ID: 12107842
[TBL] [Abstract][Full Text] [Related]
2. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.
Donskov F; Bennedsgaard KM; Hokland M; Marcussen N; Fisker R; Madsen HH; Fode K; von der Maase H
Cancer Immunol Immunother; 2004 Aug; 53(8):729-39. PubMed ID: 15088127
[TBL] [Abstract][Full Text] [Related]
3. HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.
Janssen RA; Buter J; Straatsma E; Heijn AA; Sleijfer DT; de Vries EG; Mulder NH; The TH; de Leij L
Cancer Immunol Immunother; 1993; 36(3):198-204. PubMed ID: 8439981
[TBL] [Abstract][Full Text] [Related]
4. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
[TBL] [Abstract][Full Text] [Related]
5. Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2.
van Bezooijen RL; Goey H; Stoter G; Hermans J; Fleuren GJ
Cancer Immunol Immunother; 1996 Dec; 43(5):293-8. PubMed ID: 9024506
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma.
Hermann GG; Geertsen PF; von der Maase H; Zeuthen J
Cancer Immunol Immunother; 1991; 34(2):111-4. PubMed ID: 1760814
[TBL] [Abstract][Full Text] [Related]
7. High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets.
Mertens WC; Banerjee D; al-Mutter N; Stitt L; Bramwell VH; Lala PK
Cancer Immunol Immunother; 1995 Nov; 41(5):271-9. PubMed ID: 8536272
[TBL] [Abstract][Full Text] [Related]
8. Immunological classification of renal cell carcinoma patients based on phenotypic analysis of immune check-point molecules.
Kawashima A; Kanazawa T; Goto K; Matsumoto M; Morimoto-Okazawa A; Iwahori K; Ujike T; Nagahara A; Fujita K; Uemura M; Nonomura N; Wada H
Cancer Immunol Immunother; 2018 Jan; 67(1):113-125. PubMed ID: 28975380
[TBL] [Abstract][Full Text] [Related]
9. Reversible anergy in circulating lymphocytes of cancer patients during interleukin-2 therapy.
Clementi E; Bucci E; Citterio G; Landonio G; Consogno G; Fortis C
Cancer Immunol Immunother; 1994 Sep; 39(3):167-71. PubMed ID: 7923246
[TBL] [Abstract][Full Text] [Related]
10. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells.
McCune CS; O'Donnell RW; Marquis DM; Sahasrabudhe DM
Cancer Immunol Immunother; 1990; 32(1):62-6. PubMed ID: 2289200
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma.
Xu J; Zhang W; Tong J; Liu C; Zhang Q; Cao L; Yu J; Zhou A; Ma J
Cancer Immunol Immunother; 2024 Apr; 73(6):107. PubMed ID: 38642109
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis.
Rebuzzi SE; Signori A; Stellato M; Santini D; Maruzzo M; De Giorgi U; Pedrazzoli P; Galli L; Zucali PA; Fantinel E; Carella C; Procopio G; Milella M; Boccardo F; Fratino L; Sabbatini R; Ricotta R; Panni S; Massari F; Sorarù M; Santoni M; Cortellini A; Prati V; Soto Parra HJ; Atzori F; Di Napoli M; Caffo O; Messina M; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Roviello G; Llaja Obispo MA; Porta C; Buti S; Fornarini G; Banna GL
Front Oncol; 2022; 12():955501. PubMed ID: 36212433
[TBL] [Abstract][Full Text] [Related]
13. Histamine in cancer immunology and immunotherapy. Current status and new perspectives.
Sarasola MP; Táquez Delgado MA; Nicoud MB; Medina VA
Pharmacol Res Perspect; 2021 Oct; 9(5):e00778. PubMed ID: 34609067
[TBL] [Abstract][Full Text] [Related]
14. The immunology of renal cell carcinoma.
Díaz-Montero CM; Rini BI; Finke JH
Nat Rev Nephrol; 2020 Dec; 16(12):721-735. PubMed ID: 32733094
[TBL] [Abstract][Full Text] [Related]
15. NK Cell-Based Immunotherapy in Renal Cell Carcinoma.
Terrén I; Orrantia A; Mikelez-Alonso I; Vitallé J; Zenarruzabeitia O; Borrego F
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32013092
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.
Labriola MK; Batich KA; Zhu J; McNamara MA; Harrison MR; Armstrong AJ; George DJ; Zhang T
Clin Genitourin Cancer; 2019 Jun; 17(3):e513-e521. PubMed ID: 30858035
[TBL] [Abstract][Full Text] [Related]
17. Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio.
Koo KC; Lee JS; Ha JS; Han KS; Lee KS; Hah YS; Rha KH; Hong SJ; Chung BH
World J Urol; 2019 Nov; 37(11):2375-2384. PubMed ID: 30734074
[TBL] [Abstract][Full Text] [Related]
18. In situ administration of cytokine combinations induces tumor regression in mice.
Zhang J; Jiang H; Zhang H
EBioMedicine; 2018 Nov; 37():38-46. PubMed ID: 30297145
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.
Kuzman JA; Stenehjem DD; Merriman J; Agarwal AM; Patel SB; Hahn AW; Alex A; Albertson D; Gill DM; Agarwal N
BMC Urol; 2017 Jan; 17(1):1. PubMed ID: 28056941
[TBL] [Abstract][Full Text] [Related]
20. Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.
Murphy KA; James BR; Guan Y; Torry DS; Wilber A; Griffith TS
Hum Vaccin Immunother; 2015; 11(7):1612-20. PubMed ID: 25996049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
